Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Novartis Pharmaceuticals17 enrolled

Overview

\- To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Postmenopausal Women With Advanced Breast Cancer

Interventions

LetrozoleDRUG

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 74 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Patients which participated in double blind study Exclusion Criteria: * Patients with intolerable toxicity. * Patients which confirmed progressive disease during double blind study. * Patients which have received concurrent anti-cancer therapy during double blind study.

Locations (10)

Novartis Investigative Site

Kashiwa, Chiba, Japan

Novartis Investigative Site

Amagasaki, Hyōgo, Japan

Novartis Investigative Site

Hamamatsu, Shizuoka, Japan

Novartis Investigative Site

Outcomes

Primary Outcomes

Safety during treatment

Secondary Outcomes

No secondary outcomes/objectives planned

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.